A clinical trial of a human embryonic stem cell (ESC) therapy for age-related macular degeneration has been approved by the FDA, making it the first such study for a common disease.
Author: OphthalmologyWeb
Webinar: Glaucoma Management with RTVue Fourier-Domain OCT
Featured Article
Resequencing Chip Enables Rapid Detection Of Mutations In Retinal Disease Genes
A custom resequencing chip accurately and efficiently identified novel and known mutations in retinal disease genes in multiple patients, a study conducted in the Netherlands found.
Stem Cell Trial For AMD Approved
A clinical trial of a human embryonic stem cell (ESC) therapy for age-related macular degeneration has been approved by the FDA, making it the first such study for a common disease.
Applied In Vivo Clinical Histology II: A New Way to Look at Retinal Disease
Applied In Vivo Clinical Histology I: A New Way to Look at Retinal Disease
Larry J. Alexander, OD FAAO, discusses applied in vivo clinical histology, a new way to look at retinal disease.
InSite Vision Completes Patient Enrollment In ISV-303 Phase 1/2 Clinical Study For Post-Surgical Ocular Pain And Swelling
InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company’s Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce…
InSite Vision Completes Patient Enrollment In ISV-303 Phase 1/2 Clinical Study For Post-Surgical Ocular Pain And Swelling
InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company’s Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce…
InSite Vision Completes Patient Enrollment In ISV-303 Phase 1/2 Clinical Study For Post-Surgical Ocular Pain And Swelling
InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company’s Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce…
Software Upgrade Improves Optical Biometry In Eyes With Severe Cataracts
New software enhanced optical biometry and axial length measurement in eyes slated for cataract surgery, a study found.
InSite Vision Completes Patient Enrollment In ISV-303 Phase 1/2 Clinical Study For Post-Surgical Ocular Pain And Swelling
InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company’s Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce…
Software Upgrade Improves Optical Biometry In Eyes With Severe Cataracts
New software enhanced optical biometry and axial length measurement in eyes slated for cataract surgery, a study found.
InSite Vision Completes Patient Enrollment In ISV-303 Phase 1/2 Clinical Study For Post-Surgical Ocular Pain And Swelling
InSite Vision Incorporated (OTCBB:INSV), a company developing novel ophthalmic therapeutics, today announced that patient enrollment was recently completed in the company’s Phase 1/2 clinical trial of ISV-303, a novel compound being developed to reduce…
Achieving Superior Treatment Accuracy with Navigated Photocoagulation
Igor Kozak, MD, UCSD, Jacobs Retina Center, discusses achieving superior treatment accuracy with navigated photocoagulation.
Results of 135 Eyes Treated with Diabetic Macula Edema
William R. Freeman, MD, UCSD Jacobs Retina Center, presents the results of 135 eyes treated with diabetic macula edema.
Introduction to Navigated Laser Photocoagulation
Rama D. Jager, MD, MBA, FACS, University Retina and Macula Associates, discusses the introduction to navigated laser photocoagulation.
Spectral OCT/SLO Evaluation of Diabetic Edema Patients Treated with Navigated Retinal Laser
Richard Rosen, MD, New York Eye and Ear Infirmary, discusses spectral OCT/SLO evaluation of diabetic edema patients treated with navigated retinal laser.
Intravitreal Ranibizumab Injections Safely, Effectively Treat Non-AMD CNV
Intravitreal ranibizumab showed potential benefit and a high safety profile in the treatment of choroidal neovascularization resulting from causes other than age-related macular degeneration, a study found.
Intravitreal Ranibizumab Injections Safely, Effectively Treat Non-AMD CNV
Intravitreal ranibizumab showed potential benefit and a high safety profile in the treatment of choroidal neovascularization resulting from causes other than age-related macular degeneration, a study found.
Early Detection Is Vital To Preventing Blindness
It happens slowly. Over time, a person’s vision will get worse. Until one day, that person can no longer see. Glaucoma is the second leading cause of blindness in the United States and worldwide. Unfortunately, there is no cure. Once a person’s vision …